Retraction

Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double-blind, randomized, placebo-controlled trial

Citations (4)

4
Total Citations
2
Post-Retraction
(50.0%)
1
Pre-Retraction
0
Same Day
Post-Retraction Citation Analysis
0 Within 30 days
2 Within 1 year
0 After 2+ years
296 Days since retraction (latest)
Heavy Metals Removal Using Carbon Based Nanocomposites
Unknown Authors
Unknown Journal
Published: Unknown
IUPHAR review: Drug Repurposing in Schizophrenia – An Updated Review of Clinical Trials
Jihan K. Zaki, Jakub Tomasik, Sabine Bahn
Pharmacological Research Open Access
Published: Jan 2025
1 citation
296 days after retraction
Pentoxifylline adjunct to risperidone for negative symptoms of stable schizophrenia: A randomized, double-blind, placebo-controlled trial
Ahmad Shamabadi, Elham-Sadat Rafiei-Tabatabaei, Kimia Kazemzadeh et al. (7 authors)
The International Journal of Neuropsychopharmacology Open Access
Published: Nov 2024
2 citations
235 days after retraction
Pentoxifylline as an adjunctive in treatment of negative symptoms in chronic schizophrenia: A double‐blind, randomized, placebo‐controlled trial
Mahmoud S. Abdallah, Esraa M. Mosalam, Ahmed Hassan et al. (8 authors)
CNS Neuroscience & Therapeutics Open Access
Published: Nov 2022
3 citations
490 days before retraction
Quick Stats
Total Citations: 4
Years Since Retraction: 1.7 year
Open Access: Yes
Last Checked: Jul 24, 2025
Related Papers
Left hemisphere lateralization of the limbic system and fro…
Journal of Psychiatric Research • 0 citations
Double-blind, randomized, placebo-controlled pilot study of…
CNS Neuroscience & Therapeutics • 17 citations
Allopregnanolone restores the tyrosine hydroxylase-positive…
CNS Neuroscience & Therapeutics • 11 citations
MicroRNA-219 decreases hippocampal long-term potentiation i…
CNS Neuroscience & Therapeutics • 23 citations
MicroRNA‐21 promotes glioma cell proliferation and inhibits…
CNS Neuroscience & Therapeutics • 83 citations